Top Clinical Trials companies in Switzerland by Shareholders' Equity
This ranking features the top 3 Clinical Trials companies in Switzerland ranked by Shareholders' Equity, totalling a Shareholders' Equity of USD 556.98 M, for January 15, 2025.
Switzerland
Clinical Trials
Shareholders' Equity
# |
Name |
Shareholders' Equity |
Reported Date | Stock Price |
Change |
Price (30 days) | Country |
|---|---|---|---|---|---|---|---|
| 1 |
USD 495.68 M
|
Dec. 31, 2023 | USD 46.50 | 2.74% |
|
Switzerland |
|
| 2 |
USD 209.55 M
|
Dec. 31, 2023 | USD 5.48 | 3.60% |
|
Switzerland |
|
| 3 |
USD -148.25 M
|
Dec. 31, 2023 | USD 1.71 | -0.58% |
|
Switzerland |
Frequently Asked Questions
-
Which Clinical Trials company in Switzerland has the highest Shareholders' Equity ?
The Clinical Trials company in Switzerland with the highest Shareholders' Equity is MoonLake Immunotherapeutics (NasdaqCM: MLTX) at USD 495.68 M.
-
Which Clinical Trials company in Switzerland has the lowest Shareholders' Equity ?
The Clinical Trials company in Switzerland with the lowest Shareholders' Equity is ADC Therapeutics SA (NYSE: ADCT) at USD -148.25 M.
-
What are the top 10 Clinical Trials companies in Switzerland by Shareholders' Equity ?
The top 10 Clinical Trials companies in Switzerland by Shareholders' Equity are MoonLake Immunotherapeutics, Molecular Partners AG and ADC Therapeutics SA.
-
What are the bottom 10 Clinical Trials companies in Switzerland by Shareholders' Equity ?
The bottom 10 Clinical Trials companies in Switzerland by Shareholders' Equity are ADC Therapeutics SA, Molecular Partners AG and MoonLake Immunotherapeutics.